Evidence map›Paper›PMID 40294135›Full record

ArticlePLoS biology2025

NF-κB signaling driven by oncogenic Ras contributes to tumorigenesis in a Drosophila carcinoma model.

Caroline Dillard, José Teles-Reis, Ashish Jain, Marina Gonçalves Antunes, Paula Ruiz-Duran, Yanyan Qi, Roland Le Borgne, Heinrich Jasper, Tor Erik Rusten

Abstract read
In one paragraph

Article in PLoS biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Functions ofFrontiers in cell and developmental biology · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Caroline DillardCenter for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
José Teles-ReisCenter for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Ashish JainCenter for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Marina Gonçalves AntunesCenter for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Paula Ruiz-DuranCenter for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Yanyan QiBuck Institute for Research on Aging, Novato, California, United States of America.
Roland Le BorgneUniv Rennes, CNRS-UMR, Institut de Génétique et Développement de Rennes, Rennes, France.
Heinrich JasperBuck Institute for Research on Aging, Novato, California, United States of America.
Tor Erik RustenCenter for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.ORCID https://orcid.org/0000-0002-9150-2676

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer-driving mutations synergize with inflammatory stress signaling pathways during carcinogenesis. Drosophila melanogaster tumor models are increasingly recognized as models to inform conserved molecular mechanisms of tumorigenesis with both local and systemic effects of cancer. Although initial discoveries of the Toll-NFκB signaling pathway in development and immunity were pioneered in Drosophila, limited information is available for its role in cancer progression. Using a well-studied cooperative RasV12-driven epithelial-derived tumor model, we here describe functions of Toll-NF-κB signaling in malignant RasV12, scrib- tumors. The extracellular Toll pathway components ModSP and PGRP-SA and intracellular signaling Kinase, Pelle/IRAK, are rate-limiting for tumor growth. The Toll pathway NFκB protein Dorsal as well as cactus/IκΒ show elevated expression in tumors with highest expression in invasive cell populations. Oncogenic RasV12, and not loss of scribble, confers increased expression and heterogenous distribution of two Dorsal isoforms, DorsalA and DorsalB, in different tumor cell populations. Mechanistic analyses demonstrates that Dorsal, in concert with the BTB-transcription factor Chinmo, drives growth and malignancy by suppressing differentiation, counteracting apoptosis, and promoting invasion of RasV12, scrib- tumors.

Indexed as

CarcinogenesisCarcinomaDrosophila melanogasterNF-kappa Bras ProteinsSignal TransductionAnimalsCell Transformation, NeoplasticDisease Models, AnimalDNA-Binding ProteinsDrosophila ProteinsIMP DehydrogenaseMembrane ProteinsNuclear ProteinsPhosphoproteinsToll-Like Receptorscact protein, DrosophilaDNA-Binding ProteinsDrosophila ProteinsIMP DehydrogenaseMembrane ProteinsNF-kappa BNuclear ProteinsPhosphoproteinsras protein, Drosophilaras ProteinsScrib protein, DrosophilaToll-Like ReceptorsTranscription FactorsTumor Suppressor Proteins

Identifiers

PMID40294135
PMCPMC12037074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.